Kelun Biotech is a subsidiary of Shenzhen-listed Kelun Pharmaceutical. The company secured over 500 million yuan (about $77 million) in fresh funding. The financing was led by CMC‑SDIC Capital. CMC‑SDIC Capital is a fund co‑launched by state-backed China Merchants Capital and SDIC. The lead investor announced the deal on Thursday. The article does not provide details on the use of proceeds, products, future plans, or operating metrics.

Total raised

$77M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2021